chromatin-bioscience

Chromatin Bioscience Announces Collaboration with Purespring Therapeutics

Mon, 27 Oct 2025 09:04:15 GMT

EDINBURGH, Scotland, Oct. 27, 2025

Chromatin Bioscience is pleased to announce an ongoing research collaboration with Purespring Therapeutics, a precision nephrology company leading the development of targeted, first-in-class genetic therapies to preserve kidney function. The collaboration leverages Chromatin Bio's proprietary synthetic promoter design platform, C hromatinLENS , to develop highly cell-selective promoters tailored to support Purespring's innovative gene therapy pipeline.

The partnership aims to enable precise and durable gene expression in target cell types relevant to Purespring's therapeutic strategy. While specific program details remain confidential, the project is designed to enhance the safety and efficacy of gene delivery through the integration of rationally designed synthetic promoters.

"Purespring's approach to gene therapy aligns well with our mission to provide precise gene control systems that support advanced, tissue-targeted therapeutics," said Michael Roberts, CEO and Founder of Chromatin Bioscience. "We are excited to support their efforts with our platform and help unlock the full therapeutic potential of next-generation gene therapies."

Chromatin Bioscience's C hromatinLENS platform identifies highly specific gene regulatory elements from the dark genome and integrates them into synthetic promoters optimised for target cell selectivity and expression durability. These promoters are a critical component in gene therapies where spatial and temporal control of transgene expression is essential for therapeutic success.

This collaboration with Purespring represents another milestone in Chromatin Bioscience's growing network of partnerships across the gene therapy landscape.

Chromatin Bio will be attending Advanced Therapies USA 2025 in Philadelphia

Wed, 08 Oct 2025 09:10:52 GMT

November 18-19, 2025 | Philadelphia PA, USA

The Advanced Therapies Congress USA is for the leaders of the world’s ATMP developers and their most senior executives in charge of the latest tech and strategies that are driving the industry forward.

In 2025 the event will bring 1,000 global executives together for their premier US event to be inspired by 200 speakers and 50 start-ups over 2 incredible days.

Join our CEO, Michael Roberts in Philadelphia this year and learn about Chromatin Bioscience's Gene Regulation Technology platform and partnership opportunities.

Join us in Vienna for Bio-Europe 2025

Wed, 01 Oct 2025 08:58:21 GMT

November 3-5, 2025 | Vienna, Austria

BIO-Europe will convene over 5,700 attendees, representing 60 countries and 3,000+ companies, making the event the industry's largest gathering of biopharma professionals in Europe.

Join our Director of Business Development, Kostas Drosopoulos in Vienna this year and learn about Chromatin Bioscience's Gene Regulation Technology platform and partnership opportunities.

Meet us at Cell and Gene on the Mesa 2025 in Phoenix, Arizona

Mon, 01 Sep 2025 08:50:10 GMT

October 6-8, 2025 | Phoenix, AZ, USA

The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 100+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 1,500 attendees – over 30% of which are C-level executives – this conference enables key partnerships through more than 5,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.

Join our CEO, Michael Roberts in Phoenix this year and learn about Chromatin Bioscience's Gene Regulation Technology platform and partnership opportunities.

Chromatin Bioscience Signs Collaboration Agreement with Astellas

Mon, 14 Apr 2025 15:41:43 GMT

EDINBURGH, Scotland, April 14, 2025

Chromatin Bioscience, a leader in the design of synthetic promoters and gene control systems, is pleased to announce a collaboration agreement with Astellas Pharma , a global life sciences company.

Under the agreement, Chromatin Bioscience will use its proprietary chromatinLENS platform to design cell-selective synthetic promoters aligned with Astellas' target profile. The designed promoters are expected to enable highly precise and durable gene expression in specific cell types.

"We're excited to begin this collaboration with Astellas," said Michael Roberts, CEO and Founder of Chromatin Bioscience. "We believe the ability to precisely control targeted gene expression is becoming increasingly critical across diverse applications in biotechnology. This collaboration reflects the growing interest in synthetic promoter technology as a key enabler in the development of precision-targeted biological systems."

Chromatin Bioscience's chromatinLENS platform enables the identification of gene regulatory elements from the dark genome and the rational design of synthetic promoters tailored to specific applications. The platform can be applied across a range of sectors—including therapeutics, agritech, industrial biotechnology, and bioprocessing. The collaboration with Astellas further validates the potential of the chromatinLENS platform and represents the latest milestone in a series of collaborations that are shaping Chromatin's continued growth and impact.

Join Us at the BIO International Convention 2025

Sun, 13 Apr 2025 15:37:07 GMT

June 16-19, 2025 | Boston, MA, USA

The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe.

Join our CEO, Michael Roberts and our Director of Business Development, Kostas Drosopoulos, at BIO this year in Boston and learn about Chromatin Bioscience's Gene Regulation Technology platform and partnership opportunities.

Chromatin Bio Will be Attending ASGCT 2025

Sat, 12 Apr 2025 15:30:38 GMT

May 13-17, 2025 | New Orleans, LA, USA

The American Society of Gene and Cell Therapy’s (ASGCT) Annual Meeting is the premier event for gene and cell therapy professionals. The meeting is the best place for people in the field to learn from the latest scientific research, stay current on new technologies, and make career-advancing connections with peers.

Originally designed as a venue for academic researchers to share their work, the Annual Meeting has grown to serve a wide community encompassing clinicians, bio-industry developers, regulatory agencies, equipment manufacturers, patient advocates, and more.

Our CEO, Dr Michael Roberts will be attending this year in New Orleans, LA.

Get in contact if you would like to meet up inMunich to discuss your promoter needs.

Chromatin Bio will be at the Advanced Therapies 2025, London

Tue, 11 Mar 2025 21:35:39 GMT

March 18-19, 2025 | London, UK

The Advanced Therapies Congress is Europe’s largest commercial cell and gene therapy conference and exhibition. The event is for the leaders of pioneering ATMP companies and their most senior executives in charge of the latest tech and strategies that are driving the industry forward.

With 10 tracks of content, the agenda covers everything from manufacturing, supply chain & logistics, pricing & market access, to developments in key therapeutic areas; cell therapy, gene therapy, gene modified cell therapy, immunotherapy, and much more.

Listen to our CEO, Michael Roberts give a talk on our platform, chromatinLENS, on Monday 18th at 5:30pm, or visit booth S28 to learn more about Chromatin Bio, where Kostas Drosopoulos (Director of BD) will be eager to meet with you.

If you want to arrange a meeting then please contact us .

Chromatin Bioscience Joins JLABS EMEA

Thu, 20 Feb 2025 19:30:52 GMT

EDINBURGH, Scotland, Feb. 20, 2025

Chromatin Bioscience, a leading innovator in the design of synthetic promoters and gene control systems for cell and gene therapies, is excited to announce that it has joined Johnson & Johnson’s global incubator network, JLABS EMEA as a virtual company.

JLABS is the largest global network of open innovation ecosystems, enabling and empowering emerging companies with the knowledge, experience, partnerships, and venture connections across a broad healthcare spectrum including pharmaceutical and medical technology sectors. The JLABS membership will enable Chromatin Bioscience to further accelerate its mission to enhance cell and gene therapies by enabling more precise control of therapeutic gene expression.

“We are thrilled to join the JLABS network, which offers an exceptional environment for fostering innovation and collaboration,” said Michael Roberts, CEO of Chromatin Bioscience. “This strategic membership will support our ongoing efforts to develop advanced synthetic promoter technologies that enhance the precision, safety, and efficacy of gene therapies. We look forward to leveraging JLABS’ resources to accelerate our growth and drive impactful progress in this field.”

Chromatin Bioscience’s proprietary chromatinLENS platform enables the identification of cell-selective regulatory elements from the dark genome and the design of customised synthetic promoters for targeted gene regulation. With the support of JLABS, Chromatin Bioscience is well-positioned to advance the development of its platform and continue driving impactful innovations in cell and gene therapy.

Chromatin Bioscience signs a Research Collaboration with Johnson & Johnson

Mon, 20 Jan 2025 18:56:54 GMT

We are thrilled to be working with Johnson & Johnson, a leader in global healthcare innovation.

In this project, we will leverage our proprietary chromatinLENS platform to drive advancements in synthetic promoter design and its applications in transformative healthcare solutions.

This collaboration underscores the growing recognition of our platform's potential to deliver precise, cell-type-selective, and durable gene expression, supporting innovative approaches in gene and cell therapies.

We are excited to embark on this journey with Johnson & Johnson and look forward to the opportunities this collaboration will bring.

Chromatin Bioscience’s synthetic promoter supports EsoBiotec’s ESO-T01 CAR-T therapy as it enters the clinic

ml.roberts@me.com (Michael Roberts) — Mon, 13 Jan 2025 13:07:10 GMT

Edinburgh UK, 13th January 2025.

Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T candidate into clinical trials. ESO-T01 is the first in vivo B-cell maturation antigen (BCMA) CAR-T candidate to reach the clinical stage and utilises a synthetic promoter designed using Chromatin Bio’s proprietary promoter design platform, chromatinLENS, exclusively for EsoBiotec as part of its innovative approach to immunotherapy.

EsoBiotec’s ESO-T01, developed using its ENaBL platform, is a T cell targeted lentiviral vector expressing a BCMA-targeted CAR construct for the treatment of multiple myeloma. This construct is regulated by a T cell-specific synthetic promoter developed in collaboration with Chromatin Bioscience. Early studies demonstrated highly effective in vivo transduction, with the BCMA CAR transgene expressed specifically in T cells, leading to the generation of a large population of circulating BCMA CAR-T cells that persisted throughout the study. These results highlight the long-term durability and efficacy of the engineered T cells, marking an important milestone for the therapeutic.

"ESO-T01 is the first in vivo BCMA CAR-T candidate to advance to the clinical stage, showcasing the capabilities of our ENaBL platform technology that reprograms immune cells within the body to combat cancer," stated EsoBiotec CEO Jean-Pierre Latere, Ph.D. "While various treatments exist for multiple myeloma, including ex vivo CAR-T options, many come with severe side effects and are limited by manufacturing capacity, logistical challenges, and high costs. We are excited to collaborate with Chromatin Bioscience to integrate this innovative synthetic promoter, aiming to enhance the safety and efficacy profile of ESO-T01."

Chromatin Bioscience’s chromatinLENS platform allows for the identification of highly specific, cell-type selective gene regulatory elements from the dark genome, offering significant advantages in minimising off-target effects while ensuring robust and durable therapeutic efficacy. These promoters are critical in ensuring the success of advanced therapies like ESO-T01, where targeted expression in T cells is paramount for the safety and efficacy of the treatment.

“EsoBiotec’s progress to the clinic is an exciting development in the field of gene therapy,” said Michael Roberts, CEO and Founder of Chromatin Bioscience. “Our synthetic promoters are designed to provide precision and durability in gene expression, and we are pleased that they are playing a role in ensuring the success of ESO-T01. This collaboration represents the power of combining cutting-edge gene therapy with targeted gene expression technologies to offer new treatment options for patients.”

ENDS

Notes to editors

Photo (L-R): Konstantinos Drosopoulos, Director of Business Development; Katie Baker, Principal Bioinformatics & AI/ML Engineer; Michael Roberts, CEO and Founder; Thomas Waibel, Director of Platform Technology

About Chromatin Bioscience

Chromatin Bioscience is a biotechnology company focused on the design and development of synthetic promoters for gene and cell therapies and bioprocessing. Our innovative platform enables precise, cell-type selective, and durable gene expression, which is key to advancing the next generation of gene therapies. Chromatin’s synthetic promoters have been integral in the development of therapies for a range of diseases, enhancing both safety and efficacy.

About EsoBiotec

EsoBiotec is a privately held biotechnology company that specializes in the in vivo engineering of T-cells and other immune cells to develop cost-effective, off-the-shelf therapeutics. Therapeutics are developed using the company’s Engineered NanoBody Lentiviral (ENaBL) platform to deliver state-of-the-art cell therapies and maximize accessibility to life changing cancer care. An Investigator-Initiated Clinical Trial is underway evaluating ESO-T01, EsoBiotec’s BCMA CAR-T candidate, for the treatment of multiple myeloma. EsoBiotec’s pipeline features two first-in-class, combination candidates—ESO-TX101 and ESO-TX102—designed to build on the simultaneous engineering of T cells and monocytes to remodel the tumor micro environment as treatments for solid tumors.

About ESO-T01

ESO-T01 is a third-generation replication-deficient self-inactivating lentiviral vector expressing a BCMA-targeted CAR construct under a T cell-specific synthetic promoter. It is immune shielded and resistant to phagocytosis. ESO-T01 is an “off-the-shelf” single dose treatment, directly administered systemically without the need for lymphodepletion.

For further information, please contact:

Sciad Communications, Media Relations

Maria Taylor / Juliette Craggs

E: pressteam@sciad.com

T: +44 (0)203 405 7892

Chromatin Bio will be at the Festival of Genomics

Sun, 12 Jan 2025 14:28:15 GMT

January 29-30, 2025 | London, UK

Join our Director of Platform Technology, Thomas Waibel, and Principal Bioinformatics and ML/AI Engineer, Katie Baker at the Festival of Genomics this year in London and learn about Chromatin Bioscience's chromatinLENS gene regulation platform and partnership opportunities.

Come meet Chromatin Bio at Advanced Therapy Week 2025

Fri, 03 Jan 2025 21:41:36 GMT

January 20-23, 2025 | Dallas, Texas

Join our CEO, Michael Roberts, and Director of Business Development, Kostas Drosopoulos at ATW25 this year in Dallas and learn about Chromatin Bioscience's chromatinLENS gene regulation platform and partnership opportunities.

Chromatin Bio Will Be at ESGCT 2024 in Rome

Tue, 22 Oct 2024 09:06:50 GMT

Oct 22-25, 2024 | Rome, Italy

Join our CEO, Michael Roberts, at the ESGCT meeting this year at La Nuvola and learn about Chromatin Bioscience's Gene Regulation Technology platform and partnership opportunities.

Chromatin Bio Awarded Scottish Enterprise SMART grant

Fri, 04 Oct 2024 20:28:00 GMT

Award extends company's activities in AI/ML

We are pleased to announce that Scottish Enterprise have awarded Chromatin Bio £100,000 to fund a project that aims to extend the company's platform with the introduction of a suite of AI/ML tools.

Chromatin Bio has created an integrated platform that is able to process a variety of NGS datasets and identify cell-selective and conditionally active gene regulatory elements. Then using engineering biology principles, the company can build synthetic promoters utilising these elements and create customised gene expression cassettes for its clients.

Currently the company offers this service to cell and gene therapy companies wishing to improve therapeutic construct design. Although the platform is broadly applicable across the entire biotech industry, including bio-manufacturing, industrial biotech and agriculture.

The introduction of machine learning pipelines into this process will greatly increase the efficiency of gene regulatory element discovery and improve the potency of the synthetic promoter designs, resulting in improved expression cassettes for our partners.

Join Chromatin Bio at BioEurope in Stockholm

Tue, 24 Sep 2024 13:34:49 GMT

Nov 4-6, 2024 | Stockholm, Sweden

Join our Director of Business Development, Kostas Drosopoulos, at BIO-Europe this year and learn about Chromatin Bioscience's Gene Regulation Technology platform and partnership opportunities.

Katie Baker Joins the Team at Chromatin Bio

Tue, 17 Sep 2024 16:09:31 GMT

Our New Principal Bioinformatics & AI/ML Engineer

Dr Baker specialises in the development of advanced computational tools for large-scale biological data analysis. She holds a PhD in Genomics and Bioinformatics, as well as an MSc in Artificial Intelligence. Katie’s decade long work experience spans both academia and industry, where she has contributed to numerous research and development projects and authored multiple scientific publications. Her expertise in bioinformatics has earned her several awards, including the Peter Massalski Prize and the Monogram Early Career Excellence Award. With a passion for bridging the gap between biology and AI, Katie continues to lead the development of cutting-edge tools at Chromatin Bioscience.

Chromatin Bio to attend ASGCT in Baltimore

Wed, 03 Apr 2024 14:01:23 GMT

May 7-11, 2024 | Baltimore, MD, USA

The American Society of Gene and Cell Therapy’s (ASGCT) Annual Meeting is the premier event for professionals in gene and cell therapy. The meeting, which was expanded to four full days in 2023 , is the best place for people in the field to learn from the latest scientific research, stay up to date on new technologies, and make career-advancing connections with peers.

Originally designed as a venue for academic researchers to share their work, the Annual Meeting has grown to serve a wide community encompassing clinicians, bio-industry development, regulatory agencies, equipment manufacturers, patient advocates, and more.

Our CEO, Dr Michael Roberts will be attending this year in Baltimore, MD.

Get in contact if you would like to meet up inMunich to discuss your promoter needs.

Chromatin Bio to Attend SynBioBeta in San Jose

Wed, 03 Apr 2024 13:50:18 GMT

May 6-9, 2024 | San Jose, CA, USA

The Global Synthetic Biology Conference is an innovation network that brings together individuals who share a passion for biological engineering and sustainability. We gather engineers, investors, innovators, and entrepreneurs across a broad base of industries and company sizes, who are committed to using biology to build a better world.

Our CEO, Dr Michael Roberts will be attending this year in San Jose, CA.

Get in contact if you would like to meet up inMunich to discuss your promoter needs.

Kostas Drosopoulos Joins the Team Full Time

Mon, 08 Jan 2024 17:04:46 GMT

Our Director of Business Development

Dr Drosopoulos is a seasoned professional with a strong background in drug discovery and target ID. With extensive experience in identifying and validating drug targets, Kostas has successfully worked with cross-functional teams and managed partnerships with leading pharmaceutical companies. Prior to joining Chromatin Bioscience in 2024, he worked as a Staff Scientist at the Institute of Cancer Research, where he contributed to multiple projects in cancer therapeutics. Now, as Director of Business Development at Chromatin Bioscience, Kostas leverages his scientific expertise and industry insights to foster strategic collaborations and and drive the application of Chromatin Bioscience’s innovative synthetic promoters, designed to elevate the safety, efficacy, and bioprocessing efficiency of our partners' therapeutic developments.

Chromatin Bioscience to attend BioEurope in Munich

Fri, 08 Sep 2023 10:15:24 GMT

November 6-8, 2023 | Munich, Germany

BIO-Europe convenes over 5,000 attendees, representing 60 countries and 2,220+ companies, making the event the industry's largest gathering of biopharma professionals in Europe.

Get in contact if you would like to meet up in Munich to discuss your promoter needs.

Thomas Waibel Joins Chromatin Bio

Tue, 01 Aug 2023 15:59:30 GMT

Our New Director of Platform Technology

Dr Waibel specialises in the development of synthetic gene regulation tools. He has a strong background in transcriptional control mechanisms and has extensive experience in the biotechnology sector. He joined Chromatin Bioscience as our first employee in 2023 and has been recently promoted to Director of Platform Technology. In his previous role at Synpromics, also founded by our CEO in 2010, Thomas was key in establishing the company's frameworks and successfully led the proof of concept for their synthetic promoter technology. Throughout his career, Thomas has successfully managed cross-functional teams and contributed to high-impact projects in industrial biotechnology and gene therapy. With a strong commitment to advancing engineering biology, Thomas continues to drive technological innovations at Chromatin Bioscience.

Chromatin Bioscience to speak at Biotrinity in London

Sat, 01 Apr 2023 17:53:02 GMT

April 25–26, 2023 | London, UK

BioTrinity is an established, must-attend London conference, that catalyses growth and supports in-person engagement across the life sciences industry.

The event is attended by an audience of early stage and emerging life sciences R&D Companies, investors, big pharma, and other valued partners throughout the life sciences ecosystem. The conference features a focused, relevant, and stimulating programme, led by great speakers, who bring their knowledge, expertise, and vision to the fore in exciting, high-quality sessions.

Our CEO, Dr Michael Roberts, will be speaking at the R&D Spotlight: Platforms session on Tuesday 25th April at 13:40.

Chromatin Bioscience will attend Cell and Gene on the Med in Barcelona.

Fri, 10 Feb 2023 13:13:35 GMT

April 12-14, 2023 | Barcelona, Spain

The Cell & Gene Meeting on the Mediterranean is the leading conference bringing together the ATMP community from Europe and beyond. Covering a wide range of commercialization topics from market access and regulatory issues to manufacturing and financing the sector, this program features expert-led panels, extensive one-on-one partnering capabilities, exclusive networking opportunities, and 60+ dedicated presentations by leading publicly traded and privately held companies in the space. Join ARM for Europe’s premier conference for advanced therapies.

Get in contact if you would like to meet up in Barcelona to discuss your promoter needs.

Chromatin Bioscience to attend BioEurope Spring in Basel

Thu, 09 Feb 2023 13:13:34 GMT

March 20–22, 2023 | Basel, Switzerland

BIO-Europe Spring 2023 is Europe's largest partnering conference serving the global biotech industry. The annual international event will host its edition in the city of Basel from 20 to 23 March 2023, expecting over 1,000 companies and more than 2,000 visitors and key decision-makers from across the world.

Get in contact if you want to meet up and discuss your promoter needs in Basel.

Chromatin Bioscience to provide promoter design services

Wed, 08 Feb 2023 13:13:37 GMT

Founded by Dr Michael L Roberts, FRSB

Chromatin Bioscience provides synthetic promoter design services for the biotech industry by leveraging our understanding of the genome.

The company plans to provide a bioinformatics service to its clients by custom designing synthetic promoters to client specification.

The platform technology that it developed is broadly applicable across the biotech sector and leverages eukaryotic gene regulation and functional genomics methodologies to create conditional promoters.

Get in contact to learn more about how the company can help in your construct design.